stockrowAscendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
- Revenue
- +119.9%
- EPS
- +612.3%
- Free cash flow
- +2,335.9%
- Total debt
- −41.8%
Quarter to June 2026, against a year earlier
Follow ASND
Alert me
Ascendis Pharma A/S (ASND) Operating cash flow
Ascendis Pharma A/S's operating cash flow for fiscal 2025 was $61.0M, compared with −$331.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was $404.1M. Over the past ten years it has ranged from −$522.3M (fiscal 2022) to $61.0M (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 3 consecutive fiscal years. Ascendis Pharma A/S ranks 13th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $61.0M | — |
| FY2024 | −$331.3M | — |
| FY2023 | −$505.8M | — |
| FY2022 | −$522.3M | — |
| FY2021 | −$494.1M | — |
| FY2020 | −$310.2M | — |
| FY2019 | −$197.0M | — |
| FY2018 | −$163.9M | — |
| FY2017 | −$107.5M | — |
| FY2016 | −$66.6M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $327.6M | — |
| Mar 2026 | −$9.0M | — |
| Dec 2025 | $83.8M | 4,588.22% |
| Sep 2025 | $1.8M | — |
| 42 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $1.7B |
| EXEL Exelixis, Inc. compare | $1.2B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $955.9M |
| HALO Halozyme Therapeutics, Inc. compare | $898.3M |
| ASND Ascendis Pharma A/S | $404.1M |
| BNTX BioNTech SE Sponsored ADR compare | −$277.2M |
| BBIO BridgeBio Pharma, Inc. compare | −$369.0M |
| SMMT Summit Therapeutics PLC compare | −$458.4M |
| INSM Insmed, Inc. compare | −$595.6M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on ASND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement